Dec 05, 2019
Expanding the lists of reimbursable drugs in Russia
On January 1, 2020, the order of the Government of the Russian Federation No. 2406-r comes into force approving the list of vital and essential medicines for 2020, the list of medicines for treating people with hemophilia, cystic fibrosis, pituitary dwarfism, Gaucher disease, malignant neoplasms of lymphoid, hematopoietic and related tissues, multiple sclerosis, persons after transplantation of organs and / or tissues (high-cost diseases), the list of drugs prescribed by decision of the medical commissions of medical organizations, as well as the minimum assortment of drugs needed for the provision of medical care.

The document, prepared by the Russian Ministry of Health, involves the inclusion in the list of vital and essential drugs twenty-four new drug items, which are produced by foreign manufacturers and are used to treat endocrine system diseases (two drugs), antibacterial (two drugs), antifungal (one drug) and antiviral drugs (two drugs) of systemic action, antitumor drugs (eight drugs), immunosuppressants (three drugs), psycholeptic (one drug) and drugs for the treatment of obstructive diseases (four drugs), as well as one drug for diagnostic purposes in magnetic resonance imaging and two new dosage forms are already included in the list of essential and important medications (palivizumab, abiraterone).

The anti-inflammatory drug lornoxicam for intravenous and intramuscular administration is excluded from the list of vital and essential medicines.

All of the above drugs are included in the list for free provision of citizens in stationary conditions in accordance with the rules of compulsory medical insurance.

Additionally, the list of drugs for high-cost diseases includes:
  • Three additional items (these are: imported drugs daratumumab for the treatment of chronic leukemia; alemtuzumab for the treatment of multiple sclerosis; everolimus for treatment after organ or tissue transplantation)
  • Nine drugs for the pathogenetic treatment of orphan diseases, which included in the program of high-cost diseases in 2019, two of which are produced by domestic manufacturers and are used to treat hemolytic uremic syndrome and juvenile arthritis with systemic-onset (ekulizumab, adalimumab)
  • Nine drugs of foreign manufacture for treating juvenile arthritis with systemic-onset, mucopolysaccharidosis I, II, and type VI (laronidaza, idursulfase, idursulfase beta, galsulfase, tocilizumab, canakinumab, etanercept)

See the full details here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.
This website uses cookies to ensure you get the best experience on our website. By carrying on browsing, you are giving your consent for us to set cookies.

Learn more
Ok, I agree
Subscribe to newsletter
Subscribe to our newsletter to get regular updates from us on the changes of reimbursement systems (>100 reimbursement stakeholders in 12 EU countries)